pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

immune-onc PRESS RELEASE ARCHIVE

Jun 7, 2023

Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023

Apr 14, 2023

Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023

Mar 14, 2023

Immune-Onc Therapeutics Announces IO-108 Phase I Clinical Trial Results Selected for Oral Presentation at AACR Annual Meeting 2023

Mar 3, 2023

Immune-Onc Therapeutics to Showcase Leadership in Myeloid Biology and Drug Development at Upcoming Scientific and Investor Conferences

Jan 5, 2023

Immune-Onc Therapeutics Announces Close of Series B Extension Financing, Bringing Total Round to $131 Million

Nov 10, 2022

Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting

Nov 8, 2022

Immune-Onc Therapeutics Appoints Two New Members to its Board of Directors

Oct 17, 2022

Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron

Oct 10, 2022

Immune-Onc Therapeutics Enters into Clinical Collaboration with BeiGene in China

Jul 14, 2022

Immune-Onc Therapeutics Announces Appointment of Christopher Whitmore as Chief Financial Officer and Provides Clinical Progress Update

Apr 20, 2022

Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1

Apr 19, 2022

Immune-Onc Therapeutics to Participate in the Raymond James LILRB/ILT Symposium on Myeloid Checkpoint Therapeutics in Cancer

Apr 12, 2022

Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors

Apr 8, 2022

Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Mar 9, 2022

Immune-Onc Therapeutics Announces Preclinical and Clinical Poster Presentations for IO-108, a Novel Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Feb 28, 2022

Immune-Onc Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference and the Oppenheimer 32nd Annual Healthcare Conference

Feb 17, 2022

Immune-Onc Therapeutics Receives FDA Fast Track Designation for IO-202, the First Anti-LILRB4 Myeloid Checkpoint Inhibitor, for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

Jan 31, 2022

Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors

Jan 10, 2022

Immune-Onc Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Nov 22, 2021

Immune-Onc Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Conference

Nov 9, 2021

Immune-Onc Therapeutics to Present Data Supporting Therapeutic Potential of LAIR1 Antagonist Antibodies at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Oct 13, 2021

Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients With Advanced Solid Tumors

Aug 12, 2021

Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Advanced Solid Tumors

May 4, 2021

Immune-Onc Therapeutics Appoints Stuart Lutzker, M.D., Ph.D. to Scientific Advisory Board

Apr 10, 2021

Immune-Onc Therapeutics Announces First Public Presentation of Data for its Myeloid Checkpoint Inhibitor, IO-202, in Solid Tumors at AACR21

Mar 30, 2021

Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors

Nov 10, 2020

Immune-Onc Therapeutics Announces Orphan Drug Designation of IO-202 (Anti-LILRB4) for Treatment of AML and Poster Presentation at ASH 2020

Nov 9, 2020

Immune-Onc Therapeutics to Present Preclinical Data for IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4) in Solid Tumors, at SITC 2020

Sep 16, 2020

Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial Evaluating IO-202, a First-In-Class Antibody for the Treatment of Acute Myeloid Leukemia

Aug 4, 2020

Immune-Onc Therapeutics Awarded $2.14 Million National Cancer Institute SBIR Grant to Support Development of IO-202, a First-in-Class Antibody Targeting LILRB4

May 29, 2020

Immune-Onc Therapeutics IND Application for First-In-Human Trial of IO-202, a Novel Antibody for the Treatment of Acute Myeloid Leukemia, Receives FDA Clearance

Nov 19, 2019

Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions

Oct 17, 2018

Immune-Onc Therapeutics and University of Texas Report a Novel Target for Acute Myeloid Leukemia in Nature

Sep 18, 2018

Immune-Onc Therapeutics Announces Key Executive Appointments and Series B Funding

Oct 12, 2017

Immune-Onc Therapeutics, Inc. Awarded "Buzz of BIO"

Jun 28, 2017

Immune-Onc Therapeutics, Inc. Selected to Join the Prestigious Stanford-backed StartX Community

Apr 6, 2017

Immune-Onc Therapeutics, Inc. Announces Partnership with University of Texas to Develop Novel Cancer Immunotherapy

Mar 28, 2017

Immune-Onc Therapeutics, Inc. Announces Licensing and Collaboration With Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center to Develop Novel Cancer Immunotherapy

Sep 1, 2016

Immune-Onc Therapeutics, Inc. Announces $7 Million Series A Financing

Google Analytics Alternative